FDA Approval of Tisagenlecleucel: Promise and Complexities of a $475 000 Cancer Drug. Academic Article uri icon

Overview

publication date

  • November 21, 2017

Research

keywords

  • Antineoplastic Agents
  • Drug Approval
  • Drug Costs
  • Neoplasms
  • Recombinant Fusion Proteins
  • T-Lymphocytes

Identity

Scopus Document Identifier

  • 85036542272

Digital Object Identifier (DOI)

  • 10.1001/jama.2017.15218

PubMed ID

  • 28975266

Additional Document Info

volume

  • 318

issue

  • 19